CXCL13 associated with CD20+ B cells predicted better patient survival.Combination of CD8+ T cells, CXCL13, & CXCR5 was an independent predictor for survival.Tumors with high CXCL13 expression had increased infiltration of activated and CXCR5 expressing CD8+ T cells.Murine studies: CXCL13 & anti-PD1 therapy showed a CD8+ T cell dependent retarded tumor growth with increased infiltration of cytotoxic CD8+ T cells & CXCR5-CD8+ T cells. The gene discussed is PDCD1; the disease is neoplasm.